Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
Sign Up to like & getrecommendations! Published in 2020 at "Autoimmunity reviews"
DOI: 10.1016/j.autrev.2020.102466
Abstract: Rituximab is a B cell depleting monoclonal antibody that targets the B cell-specific cell surface antigen CD20 and is currently used to treat several autoimmune diseases. The elimination of mature CD20-positive B lymphocytes committed to… read more here.
Keywords: rituximab; post rituximab; immunoglobulin; igm hypogammaglobulinemia ... See more keywords